

## Grass Pollen Allergy - Pipeline Review, H2 2018

URL:	<a href="https://marketpublishers.com/r/G8C4BE872A3EN.html">https://marketpublishers.com/r/G8C4BE872A3EN.html</a>
Date:	August 21, 2018
Pages:	65
Price:	US\$ 2,000.00
ID:	G8C4BE872A3EN

### Grass Pollen Allergy - Pipeline Review, H2 2018

#### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Grass Pollen Allergy - Pipeline Review, H2 2018, provides an overview of the Grass Pollen Allergy (Immunology) pipeline landscape.

Grass pollen allergy is a reaction which occurs soon after exposure to pollen from grasses. Signs and symptoms include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, tightening of the throat, shortness of breath or wheezing and runny nose. Predisposing factors include age, family history and other allergies.

#### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Grass Pollen Allergy - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Grass Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Grass Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 3, 1 and 2 respectively.

Grass Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

#### SCOPE

- The pipeline guide provides a snapshot of the global therapeutic landscape of Grass Pollen Allergy (Immunology).

- The pipeline guide reviews pipeline therapeutics for Grass Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Grass Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Grass Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Grass Pollen Allergy (Immunology)

## REASONS TO BUY

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Grass Pollen Allergy (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Grass Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Table of Content

- Introduction
- Global Markets Direct Report Coverage
- Grass Pollen Allergy - Overview
- Grass Pollen Allergy - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Grass Pollen Allergy - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Grass Pollen Allergy - Companies Involved in Therapeutics Development
- ALK-Abello AS
- Allergy Therapeutics Plc
- ASIT Biotech SA
- Biomay AG

HAL Allergy BV  
 Regeneron Pharmaceuticals Inc  
 Grass Pollen Allergy - Drug Profiles  
 Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile  
 Product Description  
 Mechanism Of Action  
 R&D Progress  
 BM-32 - Drug Profile  
 Product Description  
 Mechanism Of Action  
 R&D Progress  
 dupilumab - Drug Profile  
 Product Description  
 Mechanism Of Action  
 R&D Progress  
 gp-ASIT - Drug Profile  
 Product Description  
 Mechanism Of Action  
 R&D Progress  
 Pollinex Quattro Grass - Drug Profile  
 Product Description  
 Mechanism Of Action  
 R&D Progress  
 standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile  
 Product Description  
 Mechanism Of Action  
 R&D Progress  
 Vaccine 1 for Grass Pollen Allergy - Drug Profile  
 Product Description  
 Mechanism Of Action  
 R&D Progress  
 Vaccine for Grass Pollen Allergy - Drug Profile  
 Product Description  
 Mechanism Of Action  
 R&D Progress  
 Grass Pollen Allergy - Dormant Projects  
 Grass Pollen Allergy - Discontinued Products  
 Grass Pollen Allergy - Product Development Milestones  
 Featured News & Press Releases  
 Jun 25, 2018: Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy  
 May 21, 2018: Allergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging study  
 Mar 12, 2018: The quality of the results obtained in the phase III clinical study with gp-ASIT+ confirmed by the publication in the prestigious scientific journal ALLERGY  
 Feb 05, 2018: Landmark clinical study with grass pollen vaccine BM32 published  
 Jan 11, 2018: ASIT Biotech is Publishing a New Article on the Clinical Result of gp-ASIT+ in the Prestigious Science Journal ALLERGY  
 Dec 14, 2017: ASIT biotech reviews the efficacy results of gp-ASIT+ observed during the phase III trial completed in 2016  
 Dec 06, 2017: ASIT biotech significantly moves forward in the preparation of the clinical development plan of gp-ASIT+ in the US  
 Jul 03, 2017: ASIT biotech Presented the Immunogenicity Data of the gp-ASIT+ Phase III Clinical Study for the Treatment of Grass Pollen Rhinitis at EAACI 2017  
 Feb 27, 2017: ASIT biotech Will Publish the Results of the Phase 3 Clinical Trial with Its gp-ASIT+ Product

Candidate for Treating Grass Pollen Rhinitis on 28 February, 2017  
Jan 26, 2017: Biomay AG Reports Positive Results From A Second Phase IIb Trial With The Innovative 3rd Generation Grass Pollen Allergy Vaccine BM32  
Dec 05, 2016: ASIT+ technology's benefits in treating grass pollen rhinitis presented during a scientific session at Medical Research Council & Asthma UK Centre in London  
Nov 14, 2016: ASIT biotech takes important steps in US clinical development of gp-ASIT+, its lead drug candidate for grass pollen rhinitis  
Oct 05, 2016: ASIT biotech announces the last patient last visit in the Phase III clinical study with its first product candidate gp-ASIT+  
Sep 08, 2016: Grass pollen allergy vaccine also effective against hepatitis B  
Jun 27, 2016: Allergy Therapeutics announces findings from mEEC dose range finding study G204  
Appendix  
Methodology  
Coverage  
Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer

## LIST OF TABLES

Number of Products under Development for Grass Pollen Allergy, H2 2018  
Number of Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018  
Number of Products by Stage and Target, H2 2018  
Number of Products by Stage and Mechanism of Action, H2 2018  
Number of Products by Stage and Route of Administration, H2 2018  
Number of Products by Stage and Molecule Type, H2 2018  
Grass Pollen Allergy - Pipeline by ALK-Abello AS, H2 2018  
Grass Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H2 2018  
Grass Pollen Allergy - Pipeline by ASIT Biotech SA, H2 2018  
Grass Pollen Allergy - Pipeline by Biomay AG, H2 2018  
Grass Pollen Allergy - Pipeline by HAL Allergy BV, H2 2018  
Grass Pollen Allergy - Pipeline by Regeneron Pharmaceuticals Inc, H2 2018  
Grass Pollen Allergy - Dormant Projects, H2 2018  
Grass Pollen Allergy - Discontinued Products, H2 2018

## LIST OF FIGURES

Number of Products under Development for Grass Pollen Allergy, H2 2018  
Number of Products under Development by Companies, H2 2018  
Number of Products by Routes of Administration, H2 2018  
Number of Products by Stage and Routes of Administration, H2 2018  
Number of Products by Molecule Types, H2 2018  
Number of Products by Stage and Molecule Types, H2 2018

## COMPANIES MENTIONED

ALK-Abello AS  
Allergy Therapeutics Plc  
ASIT Biotech SA  
Biomay AG  
HAL Allergy BV  
Regeneron Pharmaceuticals Inc

### I would like to order:

**Product name:** Grass Pollen Allergy - Pipeline Review, H2 2018  
**Product link:** <https://marketpublishers.com/r/G8C4BE872A3EN.html>  
**Product ID:** G8C4BE872A3EN  
**Price:** US\$ 2,000.00 (Single User License / Electronic Delivery)

*If you want to order Corporate License or Hard Copy, please, contact our Customer Service: [office@marketpublishers.com](mailto:office@marketpublishers.com)*

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/G8C4BE872A3EN.html>

### To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
E-mail:  
Company:  
Address:  
City:  
Zip/Post Code:  
Country:  
Tel:  
Fax:  
Your message:

\* All fields are required

Customer Signature \_\_\_\_\_

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at [https://marketpublishers.com/docs/terms\\_conditions.html](https://marketpublishers.com/docs/terms_conditions.html)

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**